THE EPIC STUDY

EVALUATING A NEW STUDY DRUG FOR A SICKLE CELL CRISIS



INFORMATION FOR FAMILIES



What Is A Clinical Trial?

Medical research study for new treatments

 Conducted to determine if a treatment is safe and effective

 U.S. federal agencies oversee medical research

Participation is always voluntary





The EPIC Study of MST-188

- MST-188 is a new investigational agent given during sickle cell crisis
- Aim of the EPIC Study is to evaluate if MST-188 can shorten the duration of a crisis
- Individuals 4 to 65 years old
- MST-188 is given in addition to regular pain management and treatment
- No cost to participants





If MST-188 is Successful ...

It will be a new drug to help treat a painful sickle cell crisis.

- May improve blood flow
- Crisis may end sooner
- Could shorten time in the hospital





Normal vs Sickle Red Blood Cells

Normal red blood cells

- Soft and flexible
- Deliver oxygen well
- Live 30-90 days



Sickled red blood cells


- Rigid and sickle-shaped
- Deliver oxygen poorly
- Sticky surfaces
- Live 10-12 days





What is Sickle Cell Crisis?

- Also known as "Vaso-Occlusive Crisis"
- Red blood cells clump together
- Cells block blood flow



ARTIST ILLUSTRATION



The Most Common Symptom of Sickle Cell Crisis is Pain



Complications of Inadequate Blood Flow

Short Term

- Acute chest syndrome
- Anemia
- Fatigue/tiredness

Long Term

- Bone disease
- Lung disease
- Organ failure
- Stroke

CIRCULATION AND SICKLE CELL DISEASE



- Current medications for sickle cell crisis are primarily for pain management
- New therapies that shorten the duration of a crisis and improve blood flow are needed

Common Therapies:

Medications

- Bronchodilators
- Oral pain medicine and patient-controlled analgesia
- Steroids

Treatments

- Blood transfusions
- IV fluids
- Oxygen






What Does MST-188 Do?


MST-188 attaches to damaged areas of cell surfaces

MST-188 (Purified Poloxamer 188)





Laboratory Studies of MST-188 Show it Increases Blood Flow




Without MST-188


With MST-188



MST-188 May Shorten the Length of a Sickle Cell Crisis



Before MST-188



After MST-188



Previous MST-188 Experience in Sickle Cell Disease

- More than 200 sickle cell patients
- Over 70 children with sickle cell disease
- MST-188 was generally well tolerated in prior clinical trials
- Speak with your doctor for information about specific safety findings and adverse events observed in prior clinical trials





Who Can Participate?

- Patients with sickle cell disease
- At least 4 years old and no older than 65
- Hospitalized for a crisis no more than 6 times in the past 6 months

Talk to your doctor about other criteria





What Will Happen During Participation?

- All patients receive the standard care for crisis
- Regular pain management will be given
- Half of the patients will ALSO receive MST-188
- No cost or obligation to participate
- Blood samples will be taken at designated times

Talk to your doctor about specific safety findings and adverse events observed in prior clinical trials





How Many Patients Will Participate in the EPIC Study?

 388 patients will be treated in a hospital setting in the U.S. and other countries

194 patients will receive MST-188





Why Participate in the EPIC Study?

- All participants will receive standard pain management
- May be able to leave the hospital sooner
- No cost to participate
- Your participation may help others with sickle cell disease





How to Sign Up for the EPIC Study

Talk to your doctor and study nurse about the consenting process





What To Do If A Crisis May Be Starting

- Immediately contact your doctor
- Go to the study hospital as soon as your doctor advises
- It is important to go to the study hospital within 24 hours of the start of pain





Who to Call

Who to Call:

Name: Dr. Charles Quinn

Phone: 513-636-6770

Where to go:

Name: Cincinnati Children's Hospital Medical Center

Address: 3333 Burnet Avenue, Cincinnati, OH 45229





When You Need Information about EPIC

- Always call the study contact number first
- The study team is your primary source of information
- Call your doctor for additional information about the study or your situation





Information About Sickle Cell Disease



The EPIC study.com



Centers for Disease Control and Prevention



Children's Sickle Cell Foundation



National Human Genome Research Institute



National Institute of Health



Sickle Cell Disease Association of America



THE EPIC STUDY

EVALUATING A NEW STUDY DRUG FOR A SICKLE CELL CRISIS



Thank You